Zobrazeno 1 - 4
of 4
pro vyhledávání: '"D. O. Yurlov"'
Autor:
S. A. Protsenko, E. N. Imyanitov, A. I. Semenova, D. Kh. Latipova, A. V. Novik, D. O. Yurlov, A. P. Oganesian
Publikováno v:
Медицинский совет, Vol 0, Iss 20, Pp 54-61 (2020)
Melanoma of the skin is one of the most aggressive malignant neoplasms. Metastatic skin melanoma has an extremely poor clinical prognosis with a high mortality rate, accounting for 80% of all deaths from skin malignancies. The approaches to the treat
Externí odkaz:
https://doaj.org/article/b0018e303c634f01befa2d7bfd783831
Autor:
N. V. Mitiushkina, I. A. Stepanov, D. O. Yurlov, E. A. Filippova, S. V. Odintsova, A. M. Lozhkina, S. V. Orlov, A. G. Iyevleva
Publikováno v:
Сибирский онкологический журнал, Vol 19, Iss 4, Pp 132-137 (2020)
Introduction. Translocations of ALK receptor tyrosine kinase occur in approximately 5–9 % of lung adenocarcinomas. The use of ALK inhibitors usually results in the reduction of tumor size. Nevertheless, the extent and duration of response can vary
Externí odkaz:
https://doaj.org/article/031eb41cb88046efac51b21b066f0b82
Autor:
Z. S. Kotova, T. Yu. Semiglazova, I. A. Baldueva, D. H. Latipova, D. O. Yurlov, V. V. Semiglazov, G. M. Teletaeva, A. V. Novik, A. I. Semenova, S. A. Protsenko
Publikováno v:
Медицинский совет, Vol 0, Iss 10, Pp 172-175 (2018)
The aim of this study is to analyse the efficacy of efferent therapy (hemosorption) as part of drug treatment in patients with metastatic colorectal cancer (mCRC) based on the use of standard first-line chemotherapy combined with the bevacizumab bios
Externí odkaz:
https://doaj.org/article/4b8d8806db7444a88919e0781d762df9
Autor:
T. Yu. Semiglazova, Gulfiya Midhatovna Teletaeva, Vladislav Semiglazov, D. O. Yurlov, Irina Alexandrovna Baldueva, Dilorom Latipova, Svetlana Protsenko, Z. S. Kotova, Alexey Viktorovich Novik, Anna Semenova
Publikováno v:
Медицинский совет, Vol 0, Iss 10, Pp 172-175 (2018)
The aim of this study is to analyse the efficacy of efferent therapy (hemosorption) as part of drug treatment in patients with metastatic colorectal cancer (mCRC) based on the use of standard first-line chemotherapy combined with the bevacizumab bios